Core Insights - The company reported a total revenue of 743 million yuan in 2024, representing a year-on-year growth of 5.44%, but the net profit attributable to shareholders was a loss of 510 million yuan, an increase in loss of 29.34% compared to the previous year [1] - Despite progress in innovative drug research and global market expansion, the company faces significant challenges due to ongoing losses and high R&D costs [1][5] Group 1: Innovative Drug Development - The company continued to advance its innovative drug development in 2024, achieving several milestones, including the approval of its first national Class 1 innovative drug, Beta Ning® (Citrulline Bevacizumab Injection), by NMPA for acute coronary syndrome patients [4] - BAT1706 (Bevacizumab) and BAT1806 (Tocilizumab) received marketing approvals from EMA and ANVISA, respectively, allowing for sales in the US, Europe, and Brazil [4] - However, the commercialization process for these innovative drugs remains slow, with BAT1806 generating only 1.1 million USD in revenue in the US market in 2024 [4] Group 2: Global Market Expansion - The company actively expanded its global market presence in 2024, entering into licensing agreements with several international firms, such as Macter International Limited for BAT1706 in Pakistan and Afghanistan, and STADA Arzneimittel AG for BAT2506 (Golimumab) in the EU, UK, and Switzerland [4] - These partnerships are expected to enhance the company's global product coverage, although their short-term revenue contribution is limited [4] Group 3: Financial Performance - The company's gross profit for 2024 was 514 million yuan, reflecting a year-on-year increase of 0.59%, but the net loss attributable to shareholders widened to 510 million yuan [5] - High R&D expenditures and commercialization costs are the primary reasons for the ongoing losses [5] Group 4: Production Capacity and Cost Pressure - The company continued to upgrade its production lines in 2024, with the Yonghe Phase II expansion project achieving a total production capacity of 66,500 liters, enhancing production capabilities [6] - The company has also obtained GMP certification from major global regulatory bodies, including NMPA, FDA, and EMA, ensuring access to key pharmaceutical markets [6] - However, the ongoing upgrades and GMP certification efforts have resulted in significant cost pressures, with a non-deductible net profit loss of 556 million yuan in 2024, an increase of 17.76% year-on-year [6]

FANGDA PARTNERS http://www.fangdalaw.com 中国广东省广州市天河区珠江新城 电子邮件 E-mail: email@fangdalaw.com 珠江东路 6 号广州周大福金融中心 66 楼 01-06 单元 电 话 Tel.: 86-20-3225 3888 邮政编码: 510623 传 真 Fax: 86-20-3225 3899 文 号 Ref.: Unit 01-06, 66F, Guangzhou CTF Finance Centre, No.6 Zhujiang East Road, Zhujiang New Town, Tianhe District, Guangzhou, Guangdong, P.R. China 510623 上海市方达（广州）律师事务所 关于百奥泰生物制药股份有限公司 2025 年第一次临时股东大会的法律意见书 致：百奥泰生物制药股份有限公司 真实、准确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误导性 陈述或者重大遗漏，并承担相应法律责任。 本法律意见书仅供公司为本次股东大会之目的使用。未经本所事先书面同意， 本法律意见书不得 ...